These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33368924)

  • 21. Perspectives of patients, care partners, and primary care physicians on management of mild cognitive impairment and mild Alzheimer's disease dementia.
    Brunton S; Pruzin JJ; Alford S; Hamersky C; Sabharwal A; Gopalakrishna G
    Postgrad Med; 2023 Jun; 135(5):530-538. PubMed ID: 37219410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European Projects for Patients with Dementia and Their Caregivers.
    Tsolaki M; Makri M; Tsatali M; Teichmann Β
    Adv Exp Med Biol; 2023; 1425():609-618. PubMed ID: 37581834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients.
    Boccardi M; Nicolosi V; Festari C; Bianchetti A; Cappa S; Chiasserini D; Falini A; Guerra UP; Nobili F; Padovani A; Sancesario G; Morbelli S; Parnetti L; Tiraboschi P; Muscio C; Perani D; Pizzini FB; Beltramello A; Salvini Porro G; Ciaccio M; Schillaci O; Trabucchi M; Tagliavini F; Frisoni GB
    Eur J Neurol; 2020 Mar; 27(3):475-483. PubMed ID: 31692118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI).
    Arevalo-Rodriguez I; Smailagic N; Roqué-Figuls M; Ciapponi A; Sanchez-Perez E; Giannakou A; Pedraza OL; Bonfill Cosp X; Cullum S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD010783. PubMed ID: 34313331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic test accuracy of telehealth assessment for dementia and mild cognitive impairment.
    McCleery J; Laverty J; Quinn TJ
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013786. PubMed ID: 34282852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners.
    Cox CG; Salazar CR; Birnbaum AI; Witbracht M; Tam SP; Thai GT; Sajjadi SA; Gillen DL; Grill JD
    J Prev Alzheimers Dis; 2024; 11(2):285-293. PubMed ID: 38374734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia.
    Mormont E; Bier JC; Bruffaerts R; Cras P; De Deyn P; Deryck O; Engelborghs S; Petrovic M; Picard G; Segers K; Thiery E; Versijpt J; Hanseeuw B
    Acta Neurol Belg; 2020 Oct; 120(5):1157-1163. PubMed ID: 32715405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Awareness disorders in Alzheimer's disease and in mild cognitive impairment].
    Jacus JP; Dupont MP; Herades Y; Pelix C; Large H; Baud M
    Encephale; 2014 Apr; 40(2):180-7. PubMed ID: 24630532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
    Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
    Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
    Ketchum FB; Chin NA; Grill J; Gleason CE; Erickson C; Clark LR; Paulsen JS; Kind AJH
    Alzheimers Dement; 2022 Oct; 18(10):1969-1979. PubMed ID: 35213786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mild cognitive impairment: the Manchester consensus.
    Dunne RA; Aarsland D; O'Brien JT; Ballard C; Banerjee S; Fox NC; Isaacs JD; Underwood BR; Perry RJ; Chan D; Dening T; Thomas AJ; Schryer J; Jones AM; Evans AR; Alessi C; Coulthard EJ; Pickett J; Elton P; Jones RW; Mitchell S; Hooper N; Kalafatis C; Rasmussen JGC; Martin H; Schott JM; Burns A
    Age Ageing; 2021 Jan; 50(1):72-80. PubMed ID: 33197937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease.
    Popescu SG; Whittington A; Gunn RN; Matthews PM; Glocker B; Sharp DJ; Cole JH;
    Hum Brain Mapp; 2020 Oct; 41(15):4406-4418. PubMed ID: 32643852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
    Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
    Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.